Eisai Inc., is the U.S. subsidiary of an established Japanese pharmaceutical company that combines the innovative spirit of an entrepreneurial venture organization with the expertise and resources of a fully integrated pharmaceutical business. Dedicated to two therapeutic areas, Oncology and Neurology, we are relentless in our efforts to break through on a number of fronts from immuno-oncology to Alzheimer’s disease and dementia, to sleep health and epilepsy.
Eisai Co., Ltd. (Tokyo) is a leading global research and development based pharmaceutical company with approximately 10,000 employees worldwide and 14 drug discovery centers globally. Our U.S. headquarters are located in Woodcliff Lake, N.J. with commercial operations, clinical development and corporate functions. We also have three discovery centers in North America, as well as production and distribution centers.
As a research-based company, the majority of our medicines are developed in house. Our unique business model includes forging strategic partnerships with biotech, pharma companies and academia to bring new products and innovations to patients in the disease areas we serve. We believe in collaboration, in the power of people to achieve things collectively that cannot be achieved alone, and in having a long-term vision. Our aim is to provide human health care.
Our U.S. researchers are working to provide innovative solutions and tailored medicines using the most advanced technology and targeted science available in human genetics, human biology, precision chemistry and emerging biologics. Our three discovery centers are at the forefront of emerging science in Oncology & Neurology: The Eisai Center for Genetics Guided Dementia Discovery (G2D2) in Cambridge, MA; H3 Biomedicine in Cambridge, MA; and Epochal Precision Anti-Cancer Therapeutics (EPAT) in Exton, PA.
Our pipeline represents our unstoppable spirit as we strive to break through society’s most-difficult health care challenges. We are committed to breaking through for everyone with loved ones waiting for a cure